甲状腺癌
医学
甲状腺
耐火材料(行星科学)
恶性肿瘤
靶向治疗
癌症
肿瘤科
内科学
内分泌系统
癌症研究
激素
生物
天体生物学
出处
期刊:Int J Radiat Med Nucl Med
日期:2016-05-25
卷期号:40 (3): 202-207
标识
DOI:10.3760/cma.j.issn.1673-4114.2016.03.009
摘要
Thyroid cancer is the most common endocrine malignancy, and ninety percent is differentiated thyroid cancer. Surgery, radioactive iodine treatment, TSH suppressive therapy is one of the trilogies of differentiated thyroid cancer treatment. Although the diagnosis and treatment of differentiated thyroid cancer is very mature, there are some patients cannot benefit from the radioactive iodine treatment naming RAI-refractory DTC. For these patients showing dedifferentiated and a lower level of iodine uptake now use targeted drugs achieving curative effect. The studies of molecular pathology of thyroid provide a theoretical basis for the diagnosis and treatment of thyroid cancer. This review comprehensively discussing the progress of molecular targeted therapy about refractory thyroid cancer.
Key words:
Thyroid neoplasms; Protein-tyrosine kinase; Molecular targeted therapy
科研通智能强力驱动
Strongly Powered by AbleSci AI